Sigma-Tau wins US FDA OK for rare eye disease treatment
This article was originally published in Scrip
Executive Summary
The US FDA has granted Sigma-Tau Pharmaceuticals the go-ahead to market its topical ophthalmic therapeutic Cystaran (cysteamine ophthalmic solution) as a treatment for patients with corneal cystine crystal accumulation as a result of cystinosis, a rare genetic lysosomal storage disease that affects about 300 children and young adults in the US and about 2,000 people worldwide.